Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hepatitis C 2Waldenstrom Macroglobulinemia 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Liver Diseases 1

Interventions

Cyclophosphamide 117Rituximab 115fludarabine phosphate 79Peripheral Blood Stem Cell Transplantation 71Mycophenolic Acid 55Whole-Body Irradiation 52Filgrastim 49Tacrolimus 43Cyclosporine 43Radiotherapy 41Busulfan 41Antilymphocyte Serum 38Etoposide 36Melphalan 34Lenalidomide 31Methotrexate 25fludarabine 23Cord Blood Stem Cell Transplantation 22Bortezomib 20Flow Cytometry 19Cytarabine 19Methylprednisolone 18Bendamustine Hydrochloride 18obinutuzumab 17Prednisone 15Granulocyte Colony-Stimulating Factor 15Carmustine 15sargramostim 14orelabrutinib 14Therapeutics 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, B-Cell, Marginal Zone × ledipasvir, sofosbuvir drug combination × Clear all
NCT03261349 2017-08-25

Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma

National Taiwan University Hospital

Phase 2 Unknown
21 enrolled
Lymphoid

Hepatitis C, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡